The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017:
- 46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017:
- Gazyva (obinutuzumab): Used to treat follicular lymphoma
- Lynparza (olaparib): Used to treat ovarian cancer
- 177 joint negotiations have been completed with 7 new files added since the last update of September 30, 2017:
- Erelzi (etanercept): Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis
- Humira (adalimumab): Used to treat hidradenitis suppurativa
- Prolia (denosumab): Used to treat osteoporosis
- Repatha (evolocumab): Used to treat primary hyperlipidemia and mixed dyslipidemia
- Invokamet (canagliflozin/metformin hydrochloride): Used to treat type 2 diabetes mellitus
- Kalydeco (ivacaftor): Used to treat cystic fibrosis with G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R or R117H mutation
- Kevzara (sarilumab): Used to treat rheumatoid arthritis
- 55 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of September 30, 2017.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of September 30, 2017.
For more information, please consult the pCPA’s website.